Shibuya Keiko, Hiraoka Masahiro
Dept. of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2007 Apr;34(4):544-9.
Radiation therapy is one of the most important modalities for the treatment of lung cancer. Current progress of radiation therapy in cooperation with the development of physics and biology is remarkable. The techniques of three-dimensional treatment planning and three-dimensional conformal radiotherapy (3D-CRT) have facilitated the use of higher radiation doses. Patients with early-stage non-small cell lung cancer (NSCLC) are candidates for curative surgical resection. However, the number of elderly patients has been increasing, and these patients often have medical contraindications that prevent curative surgery. Recently, several clinical trials on stereotactic body radiotherapy (SBRT) using the 3D-CRT technique for solitary lung tumors have been reported. The local control rate for stage I disease is more than 90%, and survival rates are promising. Now a prospective multi-institutional trial is ongoing to determine whether this modality can become a standard treatment for inoperable patients or an alternative to lobetectomy. For locally advanced NSCLC, unfortunately, recent studies have demonstrated that conventional therapies may have reached a therapeutic plateau. Now several radiation dose escalation studies utilizing conventional fractionation and 3D-CRT techniques are ongoing. The strategies of almost all of these trials are to eliminate elective nodal irradiation and deliver a higher dose of radiation to gross tumor volume while sparing normal tissues. Preliminary experience has resulted in promising survival, but should be developed to integrate into the combined treatment to completely control both local disease and other microscopically involved lesions. The combination of novel chemotherapeutic agents and molecular targeting therapies with radiation therapy is being investigated. Development of molecular imaging techniques is expected to facilitate more selective dose escalation in tumors.
放射治疗是肺癌治疗最重要的手段之一。当前,放射治疗与物理和生物学发展相结合取得了显著进展。三维治疗计划和三维适形放射治疗(3D-CRT)技术促进了更高放射剂量的应用。早期非小细胞肺癌(NSCLC)患者是根治性手术切除的候选对象。然而,老年患者数量一直在增加,这些患者往往存在妨碍根治性手术的医学禁忌证。最近,已有多项关于使用3D-CRT技术对孤立性肺肿瘤进行立体定向体部放射治疗(SBRT)的临床试验报告。I期疾病的局部控制率超过90%,生存率也很可观。目前正在进行一项前瞻性多机构试验,以确定这种治疗方式是否能成为无法手术患者的标准治疗方法或肺叶切除术的替代方法。遗憾的是,对于局部晚期NSCLC,最近的研究表明传统疗法可能已达到治疗平台期。现在有几项利用常规分割和3D-CRT技术的放射剂量递增研究正在进行。几乎所有这些试验的策略都是消除选择性淋巴结照射,在保护正常组织的同时向大体肿瘤体积给予更高剂量的放射治疗。初步经验已带来了有前景的生存率,但应进一步发展以纳入联合治疗,从而完全控制局部疾病和其他显微镜下受累病灶。新型化疗药物和分子靶向治疗与放射治疗的联合应用正在研究中。分子成像技术的发展有望促进在肿瘤中更有选择性地增加剂量。